Abstract Number: L16 • ACR Convergence 2023
Withdrawal of Immunosuppressant and Low-dose Steroids in IgG4-RD Patients with Stable Disease (WInS IgG4-RD): An Investigator-initiated, Multi-center, Open-label, Randomized Controlled Trial
Background/Purpose: IgG4-related disease (IgG4-RD) is a fibroinflammatory disease. Remission induction treatment with glucocorticoid (GC) is usually effective, but its tendency of relapse makes the strategy…Abstract Number: 1956 • ACR Convergence 2023
Rituximab Treatment in Adult Patients with Idiopathic Inflammatory Myositis (IIM): A Systematic Review and Meta-analysis
Background/Purpose: Autoimmune myositis involves a spectrum of rare autoimmune disorders characterized by inflammation and damage to skeletal muscles. The management of these challenging conditions often…Abstract Number: 2165 • ACR Convergence 2023
Efficacy of Abatacept in Rheumatoid Arthritis- associated Usual Interstitial Pneumonia. National Multicenter Study of 233 Patients During a Long-Term Follow Up
Background/Purpose: Interstitial lung disease (ILD) is a severe extra-articular manifestation of rheumatoid arthritis (RA). Usual interstitial pneumonia (UIP) is the most frequent, and severe ILD…Abstract Number: PP05 • ACR Convergence 2023
Relief Redefined: A Patient’s Journey to Reducing the Impact of Her PsA Flare Ups
Background/Purpose: I was diagnosed with Psoriatic Arthritis (PsA) ten years ago, at 25. I had been dealing with stiffness and chronic fatigue for most of…Abstract Number: 0423 • ACR Convergence 2023
Detection of Citrullinated Proteins Recognized by a Novel Chimeric Antigen Receptor TregTherapy in Both Synovial Fluid and Serum from Patients with Rheumatoid Arthritis
Background/Purpose: Rheumatoid arthritis (RA) is one of the most common autoimmune diseases and despite many therapeutic options, an unmet medical need persists for novel therapies…Abstract Number: 0436 • ACR Convergence 2023
Patients with Difficult-to-treat Rheumatoid Arthritis Have Higher Levels of Inflammation on Ultrasound
Background/Purpose: With increasing numbers of advanced therapies, rheumatologists frequently see Rheumatoid Arthritis (RA) patients who have failed ≥2 advanced therapies with different mechanisms of action.…Abstract Number: 0585 • ACR Convergence 2023
The Impact of Impaired Vagus Nerve Activity and Transcutaneous Vagus Nerve Stimulation (tVNS) on Arterial Stiffness in Systemic Lupus Erythematosus (SLE)
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic inflammatory autoimmune disease with an increased risk of atherosclerosis. The development of atherosclerosis in SLE cannot be…Abstract Number: 0677 • ACR Convergence 2023
Analysis of Clinical Outcomes in Eosinophilic Granulomatosis with Polyangiitis (EGPA) Treated with Mepolizumab over 2 Years for Remission Induction or Maintenance: A Single Center Experience in Japan
Background/Purpose: Contrary to Western countries, MPO-ANCA-associated vasculitis (MPO-AAV) is dominant in Japan or Asian countries. It is possible that therapeutic responses to EGPA with mepolizumab…Abstract Number: 0837 • ACR Convergence 2023
A Randomized, Double-Blind, Sham-Controlled, Clinical Trial of Auricular Vagus Nerve Stimulation for the Treatment of Active Rheumatoid Arthritis
Background/Purpose: Vagus nerve stimulation (VNS) has emerged in recent decades as a potential therapy for RA.We have previously shown that auricular VNS produced an average…Abstract Number: 0856 • ACR Convergence 2023
Dupilumab for Relapsing or Refractory Eosinophilic Granulomatosis with Polyangiitis: A European Retrospective Study
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is an ANCA-associated vasculitides characterized by asthma, blood and tissue eosinophilia and systemic manifestations. Glucocorticoids (GCs)-dependent asthma and/or disabling…Abstract Number: 0870 • ACR Convergence 2023
Targeting Peroxisome Proliferator-Activated Receptor α Is a Disease-Modifying Therapy for Osteoarthritis
Background/Purpose: Disease-modifying therapeutic agents to prevent progression of Osteoarthritis (OA) are an urgent clinical need. Targeting senescence and autophagy in chondrocytes with small molecules is…Abstract Number: 1121 • ACR Convergence 2023
Cardiovascular Safety of Febuxostat in Patients with Gout or Hyperuricemia: A Systematic Review of Randomized Controlled Trials
Background/Purpose: To this date, a causal relationship between febuxostat and cardiovascular disease remains controversial as comparison between trials can be challenging and may lead to…Abstract Number: 1188 • ACR Convergence 2023
Development of a Method to Isolate Functional Mitochondria and Assess Their Functionality and Integration in Joint Tissues: In Vitro and in Vivo Models
Background/Purpose: There is not cure or an efficient treatment for the osteoarthritis (OA). Mitochondrial damage and dysfunction are described during OA process modulating chondrocyte function…Abstract Number: 1200 • ACR Convergence 2023
Self-Reported Effectiveness of Cannabis for Arthritis-Related Pain
Background/Purpose: Pain management remains a significant challenge for individuals with rheumatic diseases (RDs), often causing patients to seek complementary or alternative treatments to traditional medications.…Abstract Number: 1563 • ACR Convergence 2023
Methotrexate: A Safe and Effective Therapeutic Alternative in Behçet´s Disease
Background/Purpose: Behçet's disease (BD) is characterized by great clinical heterogeneity. The therapeutic strategy for BD could be tailored to the specific needs of the patient,…
- 1
- 2
- 3
- 4
- Next Page »